Alexion Pharmaceuticals, Inc. clinical trials

Acquired by AstraZeneca, Jul 21, 2021 · source ↗

The registry lists 255 studies whose lead sponsor is Alexion Pharmaceuticals, Inc.. 24 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 255. List all 255 → · All AstraZeneca studies →

• Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)RecruitingNCT07596784Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor TherapiesRecruitingNCT05966467

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingNCT07557420Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Registry of Patients With HypophosphatasiaEnrolling by invitationNCT02306720

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• ALXN2350 in Adult Participants With BAG3-Associated Dilated CardiomyopathyRecruitingNCT07218887Phase 1/2

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid CardiomyopathyNot yet recruitingNCT07789483Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Study of Ravulizumab in Pediatric Participants With Primary IgANRecruitingNCT07024563Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.RecruitingNCT07081646Phase 1/2

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney TransplantationRecruitingNCT06830798Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)RecruitingNCT07157787Phase 2

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisRecruitingNCT07160608Phase 2

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Danicopan Early Access ProgramAvailableNCT05982938

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUSRecruitingNCT07308574Phase 4

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecruitingNCT06312644

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy ParticipantsRecruitingNCT07352423Phase 1

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabRecruitingNCT07221838Phase 4

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisRecruitingNCT06607627Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Lysosomal Acid Lipase (LAL) Deficiency RegistryRecruitingNCT01633489

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)RecruitingNCT04202341

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Prospective Sub-Study of the Global Hypophosphatasia RegistryRecruitingNCT05234567

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia GravisRecruitingNCT06967480

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac BiomarkersRecruitingNCT07306949Phase 4

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular HemolysisRecruitingNCT06449001Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Atypical Hemolytic-Uremic Syndrome (aHUS) RegistryRecruitingNCT01522183

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Study of ALXN2220 Versus Placebo in Adults With ATTR-CMActive, not recruitingNCT06183931Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Active, not recruitingNCT06291376Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney TransplantationActive, not recruitingNCT06744647Phase 2

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyTerminatedNCT07037420Phase 2

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).CompletedNCT07732361

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKETerminatedNCT05746559Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult ParticipantsCompletedNCT04933682Phase 1

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)Active, not recruitingNCT04504825Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMITerminatedNCT00546260Phase 2

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure SyndromesCompletedNCT01192425

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSDActive, not recruitingNCT05346354Phase 2/3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase AlfaActive, not recruitingNCT06079281Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantCompletedNCT04543591Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHActive, not recruitingNCT05389449Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Active, not recruitingNCT04512235Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisActive, not recruitingNCT05556096Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)Active, not recruitingNCT05981092

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CMCompletedNCT04622046Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT06578949Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaCompletedNCT05886244Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPPActive, not recruitingNCT06079359Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT05274633

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase AlfaActive, not recruitingNCT06079372Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisActive, not recruitingNCT05644561Phase 3

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy ParticipantsActive, not recruitingNCT05501717Phase 1

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca

• Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult ParticipantsCompletedNCT04958135Phase 1

  Sponsor listed in the registry: Alexion Pharmaceuticals, Inc. · First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca